Published on 29/11/2025

Understanding Supplier and Partner Roles in Chain of Identity and Chain of Custody

Introduction to Chain of Identity (COI) and Chain of Custody (COC)

Chain of Identity (COI) and Chain of Custody (COC) are critical components in ensuring the integrity, quality, and safety of biological products. For products classified as Advanced Therapy Medicinal Products (ATMPs), the emphasis on maintaining a robust COI and COC is pivotal to regulatory compliance, particularly under guidelines set forth by regulatory bodies such as the FDA, EMA, and MHRA.

COI pertains to tracking the identity of biological materials throughout the manufacturing process, ensuring that the correct cells or tissues are used in product formulation, which is essential for meeting potency identity Critical Quality Attributes (CQAs). Conversely, COC ensures that these materials are stored, transported, and handled according to adequate aseptic controls, as mandated in Annex 1 of EU GMP guidelines, thus preventing contamination or mix-ups.

The Importance of Supplier Selection in COI/COC

Choosing the right suppliers and partners is crucial for the effective management of COI and COC in pharmaceutical manufacturing processes. For biologics and ATMPs, this includes not only evaluating the suppliers’ ability to deliver quality materials consistently but also their adherence to cGMP regulations and their understanding of viral clearance validation processes.

Companies must conduct thorough assessments of potential suppliers, focusing on their manufacturing processes, quality control systems, and infrastructure used for cold chain management. For instance, assessing compliance with EMA and FDA guidelines ensures that suppliers utilize closed systems or single-use systems that minimize contamination risks, thus safeguarding COI and COC integrity.

Sourcing Materials: Biologics and ATMP Requirements

When sourcing materials for the production of biologics and ATMPs, it is vital to consider the specific requirements that govern the cold chain. Cold chain management ensures that biological materials, such as cells and viral vectors, are stored and transported under conditions that preserve their stability and efficacy. Deviations in temperature can adversely affect the characteristics of these materials, leading to compromised product quality and, potentially, patient safety issues.

Moreover, spiking studies should be employed as part of the validation process to demonstrate viral clearance capacity. These studies simulate real-world conditions under which the biological product can come into contact with viral contaminants, thereby evaluating the efficacy of the implemented controls. In this context, collaboration with suppliers that can support spiking studies is vital to ensure a thorough assessment of product safety.

Viral Clearance Validation in Biologics and ATMP Production

Viral clearance is a critical consideration for the safety of biologics and ATMPs. The validation process assesses the ability of a manufacturing process to eliminate or inactivate viruses, thereby ensuring that the final product is safe for patients. The validation process is governed by stringent guidelines such as ICH Q5A(R2), which outlines the essential principles for viral safety.

To undertake effective viral clearance validation, manufacturers must consider various models and scenarios, including the incorporation of spiking studies. Each study needs to establish parameters related to the types of viruses to be tested and the expected reduction levels for viral loads during production. Therefore, suppliers’ roles include not only providing raw materials but also offering expertise in designing and executing validation protocols that conform to international standards.

Implementing Closed and Single-Use Systems

Closed systems and single-use systems are integral to reducing risks associated with contamination and ensuring compliance with aseptic conditions during biological product manufacturing. In the context of COI and COC, closed systems help to maintain sterility by providing a continuous barrier between the product and the external environment. These systems facilitate a controlled production environment while tracking the process input and output effectively.

Similarly, single-use systems offer the advantage of reducing cross-contamination risks by utilizing disposable components that are used once and then discarded. This method not only simplifies cleaning and validation procedures but also aligns with regulatory requirements for aseptic controls. Therefore, selecting suppliers proficient in manufacturing closed or single-use systems enhances the effectiveness of COI and COC protocols.

Tailoring PPQ and CPV for ATMP Validation

Process Performance Qualification (PPQ) and Continuous Process Verification (CPV) are vital frameworks employed in the validation lifecycle of biologics and ATMPs. These frameworks ensure process consistency and product quality over time, particularly as manufacturers scale up production. For ATMPs, specific tailoring of PPQ and CPV may be required to align with the unique characteristics of the products and their manufacturing processes.

When working with suppliers on PPQ and CPV activities, it is essential to outline clear expectations regarding data collection, analysis, and documentation practices. Proper tailoring may involve adapting sampling strategies, defining acceptance criteria, and establishing procedures for addressing any deviations. By fostering collaboration with suppliers on these aspects, organizations can enhance the robustness of their validation processes, especially given the complexities associated with ATMP manufacturing.

Regulatory Compliance and Quality Assurance

An effective COI and COC strategy must align with the regulatory compliance landscape. Regular audits, documentation reviews, and strict adherence to quality assurance protocols are necessary to ensure that suppliers meet cGMP and other regulatory requirements. This oversight is particularly critical in environments subject to inspections by regulatory bodies such as the FDA and EMA.

Pharmaceutical companies should implement systematic approaches for supplier management, incorporating continuous monitoring and periodic re-evaluations of supplier performance. By maintaining a comprehensive vendor qualification program, organizations can ensure adherence to established quality standards, leading to improved outcomes in COI and COC maintenance.

Key Challenges in Managing COI and COC

Managing COI and COC in biologics and ATMP production poses several challenges that require diligent attention. Risks of contamination due to improper storage or transportation conditions must be adequately mitigated, which necessitates clear communication with suppliers regarding temperature controls and handling procedures.

Additionally, maintaining comprehensive records throughout the COI and COC processes is paramount. This documentation must include tracking information about materials, processes, and testing results, which are essential for compliance verification and audit readiness. Failure to meet documentation requirements can have severe consequences during regulatory inspections and can result in product recalls or even suspensions of production.

Conclusion: Strengthening Supplier Relationships for Effective COI/COC

The roles of suppliers and partners in maintaining effective COI and COC are of utmost importance, especially within the refined scopes of biologics and ATMP production. By establishing robust supplier relationships, organizations can ensure adherence to stringent regulatory requirements, mitigate risks, and promote product integrity.

Ultimately, companies pursuing excellence in COI and COC must prioritize supplier evaluation processes, viral clearance validation strategies, and adherence to cGMP standards. As the pharmaceutical landscape evolves, fostering close collaborations with suppliers will lead to strengthened manufacturing processes and enhanced overall patient safety.